Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to XDR-Pseudomonas aeruginosa

Jonathan D Edgeworth, Domenico Merante, Sanjay Patel, Christopher Young, Paul Jones, Seema Vithlani, Duncan Wyncoll, Peter Roberts, Andrew Jones, Tsutae Den Nagata, Mari Ariyasu, David M Livermore, Richard Beale

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)
22 Downloads (Pure)


Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase-positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.

Original languageEnglish
Pages (from-to)1932–1934
Number of pages3
JournalClinical Infectious Diseases
Issue number11
Early online date12 Nov 2018
Publication statusPublished - 1 Jun 2019


  • Cefiderocol
  • Pseudomonas aeruginosa
  • drug resistance
  • endocarditis
  • microbial

Cite this